Source page: McKinsey & Company

Commentary

Visual form

Four-panel icon-and-dot comparison chart.

Layout / body structure

The chart is arranged as four columns running left to right across the vaccine value chain. Each column places a line icon for the activity at the top, a printed count beneath it, and then a cluster of dots below, so the reader moves across the four stages in order.

What is being compared

It compares African vaccine manufacturers’ activity across four value-chain steps: drug-substance manufacturing, fill and finish, packaging and labeling, and import for distribution.

Measurement system

The measure is the approximate number of products at each value-chain step. The values are printed directly as 6, 13, 15, and 22, and the dot clusters below each icon visually scale those counts against one another.

Visible structure inside the graphic

Each value-chain step uses the same top-and-bottom construction: icon, label, number, then a matching circular dot cluster. The dark left-side clusters for the first two steps are visibly smaller than the bright blue clusters for packaging and import, which makes the imbalance easy to see even before reading the numbers.

Main takeaway from the visual

African vaccine capacity is concentrated farther downstream in packaging, labeling, and especially import for distribution rather than in drug-substance manufacturing. The left-to-right buildup across the four columns makes the value chain look strongest near the end rather than at the origin.

Key standout values or extremes

Import for distribution is the largest category at 22 products, followed by packaging and labeling at 15 and fill and finish at 13. Drug-substance manufacturing is the smallest at 6, less than half the size of the packaging count and far below the import total.

Controls / sequence, when applicable

This is a static chart image with no in-chart controls to operate.

Companion media, when applicable

There is no separate companion audio or video; the chart image is the full visual on this page.


First things first

Public Health | Manufacturing | Africa

May 3, 2021 – Vaccine manufacturing in Africa is still nascent, especially in the upstream segments of the value chain, such as antigen production and other drug-substance manufacturing processes.

Final GIF file uploaded in April folder

To read the article, see “Africa needs vaccines. What would it take to make them here?,” April 14, 2021.


customizer here